COMPANY

About Us

Mavatar was founded in 2018, building on over 20 years of research in precision medicine from the Benson Lab, where foundational research laid the groundwork for our current technology. Over time, we have refined and expanded upon this research, developing unique methods to standardize and integrate diverse data sources, setting us at the forefront of AI-driven precision medicine.

Decoding disease. Delivering precision.

Mavatar is a global specialist in AI-driven precision medicine. Our mission is to transform healthcare from a reactive, one-size-fits-all approach into predictive, personalized, and highly effective treatments—tailored for every individual across all disease areas.

Built on over 20 years of groundbreaking scientific research, Mavatar integrates advanced AI with deep molecular insights to unlock personalized care's true potential. Our proprietary DINA (Deep Integrated Network Analysis) framework underpins our two flagship platforms:

Mavatar Discovery – Accelerates drug development by unveiling hidden patterns in complex biological data, identifying new therapeutic targets, and optimizing clinical trials.

Mavatar Precision – Provides patient-specific treatment recommendations through AI-powered simulations and digital twins, enabling precise clinical decision-making.

By modeling digital twins of both patients and diseases, we empower researchers and clinicians to make more informed decisions, reducing trial-and-error, lowering healthcare costs, and significantly improving patient outcomes worldwide.

Our Company Journey

Key moments that shaped our progress and defined our path forward.

Phase One
2024

Secured a seed investment of 3,7M€ for go to market and expanded the core team.

Validation
2023

Gained significant scientific validation from industry partners, proving platform efficacy.

Pilots Begin
2022

Started crucial pilot projects with several top pharmaceutical companies.

Platform Launch
2021

Successfully launched the M-platform for creating personalized medical avatars.

Partnerships
2020

Formed key strategic partnerships with Uppsala University Hospital and Karolinska Institutet.

Initial Funding
2019

Secured initial seed funding round and established the core research & development team.

Foundation
2018

Mavatar founded by visionary team, initial development of core medical avatar technology begins.

Our Vision

We envision a future where everyone receives personalized, predictive, and effective care, powered by the convergence of biology and artificial intelligence.

Johan Juhlin talking about Mavatar

Our Culture

At Mavatar, our culture thrives on purpose-driven innovation and collaboration. Our diverse team of over 25 specialists, each holding a PhD in data science, bioinformatics, or clinical research, is united by a shared passion for transforming healthcare.

We foster an environment of openness, curiosity, and continuous learning. Our collaborative approach combines rigorous scientific thinking with creative problem-solving, encouraging each team member to contribute bold ideas and challenge conventional wisdom. Integrity, respect, and accountability form the cornerstone of our interactions—both internally and externally.

At Mavatar, we celebrate diverse perspectives and interdisciplinary collaboration, knowing that complex healthcare challenges demand the collective brilliance of many minds. Driven by a shared vision and dedication to impactful innovation, our culture empowers every specialist to grow personally and professionally while making meaningful contributions to healthcare's future.

Mavatar Employees talking in a circle

Our Leadership Team

Empowering healthcare with AI-driven insights, optimized drug discovery, and personalized treatments.

Johan Juhlin
Read More
CEO & Co-founder

Johan Juhlin

Fredrik Barrenäs
Read More
CTO & Co-founder

Fredrik Barrenäs

Danuta Gawel
Read More
Chief Research and Development Officer – Precision

Danuta Gawel

Daniel Nilsson
Read More
CFO / Legal & Co-founder

Daniel Nilsson

Linda Wakeham
Read More
Chief Marketing & Communications Officer

Linda Wakeham

Join Beta